Peripheral Dopamine in Postural Tachycardia Syndrome
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the proposed research is to determine how changes in kidney dopamine (DA)
activity influence urinary sodium excretion. We will decrease DA activity in the kidney by
inhibiting DA synthesis via carbidopa administration. We want to compare findings in normal
volunteers and in patients with postural tachycardia syndrome (POTS). We will test the null
hypothesis (Ho) that the effects of oral carbidopa administration on urinary sodium excretion
will not differ between patients with POTS and healthy volunteers.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Vanderbilt University Vanderbilt University Medical Center